{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+human+interleukin-2&page=3", "query": { "intervention": "Recombinant human interleukin-2", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 414, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+human+interleukin-2&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+human+interleukin-2&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T23:28:57.526Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02748564", "title": "Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Stage III Mucosal Melanoma of the Head and Neck", "Stage IIIA Skin Melanoma", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Skin Melanoma", "Stage IVA Mucosal Melanoma of the Head and Neck", "Stage IVB Mucosal Melanoma of the Head and Neck", "Stage IVC Mucosal Melanoma of the Head and Neck" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 10, "start_date": "2017-03-21", "completion_date": "2023-06-05", "has_results": true, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 5, "location_summary": "Maywood, Illinois • Bloomington, Indiana • Boston, Massachusetts + 2 more", "locations": [ { "city": "Maywood", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02748564" }, { "nct_id": "NCT02500576", "title": "Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Therapeutic Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2015-08-07", "completion_date": "2022-10-12", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500576" }, { "nct_id": "NCT01585415", "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Young TIL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 12, "start_date": "2012-04-09", "completion_date": "2016-07-21", "has_results": false, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585415" }, { "nct_id": "NCT00505635", "title": "Biochemotherapy With Temozolomide for Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Velban", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Intron-A", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 5, "start_date": "2007-03", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00505635" }, { "nct_id": "NCT00002589", "title": "Lymphocyte Therapy in Treating Patients With Kidney Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "muromonab-CD3", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "adjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 90, "start_date": "1994-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002589" }, { "nct_id": "NCT01118091", "title": "Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Skin Cancer", "Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "CD8 enriched Young TIL", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2010-04", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2015-10-08", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01118091" }, { "nct_id": "NCT00071890", "title": "Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Interleukin 2", "type": "DRUG" }, { "name": "HAART", "type": "DRUG" }, { "name": "Treatment interruption", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2003-10", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2010-10-05", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071890" }, { "nct_id": "NCT00072085", "title": "Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2003-09", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072085" }, { "nct_id": "NCT00006291", "title": "Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC(2)120(B,MN)GNP (vCP1452)", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": null, "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006291" }, { "nct_id": "NCT06677710", "title": "IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis", "Primary Progressive Multiple Sclerosis (PPMS)", "Secondary Progressive Multiple Sclerosis (SPMS)", "Non-Active Secondary Progressive Multiple Sclerosis", "Non-Active SPMS", "Autoimmune Diseases of the Nervous System", "Nervous System Diseases", "Autoimmune Diseases", "Demyelinating Diseases", "Immune System Diseases", "Demyelinating Autoimmune Diseases, Central Nervous System (CNS)" ], "interventions": [ { "name": "IDP-023", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indapta Therapeutics, INC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2026-06-30", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-10-05T23:28:57.526Z", "location_count": 5, "location_summary": "Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06677710" } ] }